MAJIC-PV adverse events1
| Toxicity (Events [Patients]) (≥5 patients in either arm) | JAKAFI® (ruxolitinib) (n=93) | BAT (n=87) | ||
|---|---|---|---|---|
| Grade 3 | Grade 4 | Grade 3 | Grade 4 | |
| Blood and lymphatic system disorders | 16 (11) | 0 (0) | 4 (3) | 0 (0) |
| Anemia | 12 (7) | 0 (0) | 2 (1) | 0 (0) |
| Gastrointestinal disorders | 12 (9) | 0 (0) | 9 (6) | 3 (3) |
| General disorders and administration site conditions | 6 (6) | 0 (0) | 6 (5) | 0 (0) |
| Hepatobiliary disorders | 0 (0) | 0 (0) | 5 (5) | 0 (0) |
| Infections and infestationsa | 18 (14) | 2 (2) | 4 (4) | 7 (4) |
| Injury, poisoning, and procedural complications | 9 (6) | 1 (1) | 4 (4) | 0 (0) |
| Investigations (abnormal laboratory results) | 11 (9) | 1 (1) | 2 (2) | 0 (0) |
| Metabolism and nutrition disorders | 8 (6) | 1 (1) | 6 (4) | 1 (1) |
| Musculoskeletal and connective tissue disorders | 10 (6) | 0 (0) | 2 (2) | 0 (0) |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps)a | 7 (6) | 1 (1) | 3 (3) | 1 (1) |
| Nervous system disorders | 9 (7) | 0 (0) | 8 (7) | 1 (1) |
| Respiratory, thoracic, and mediastinal disorders | 8 (5) | 1 (1) | 4 (4) | 2 (2) |
| Skin and subcutaneous tissue disorders | 13 (10) | 0 (0) | 1 (1) | 0 (0) |
| Vascular disorders | 14 (8) | 0 (0) | 7 (6) | 1 (1) |